In 2020, three large Phase III Randomized Control Trials (RCTs) that focused on neonatal red blood cell transfusions were published. Two studies evaluated the long term neurocognitive and mortality outcomes of pre-term infants receiving red blood transfusions at high and low hemoglobin thresholds. The third study assessed the use of erythrocyte stimulating agent (erythropoietin) to improve neuroprotection of extremely low birth weight infants (birth weight ≤ 1000 grams). The results of these RCTs will help shape the future of red blood cell transfusion in this highly vulnerable population. This joint AABB/ISBT session will not only discuss the results of these transformative studies but will also explore limitations of these type of trials and the future of optimizing RBC transfusion for these patients.
Franz AR, et al. JAMA. 2020;324(6):560-570. Juul SE, et al. N Engl J Med. 2020;382(3):233-243. Juul SE, et al. Jama, Pediatr. 2020;174(10):933-943.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Describe optimal pre-transfusion haemoglobin thresholds for preterm infants.
Evaluate the benefits and risks of high dose erythropoietin for premature neonates.
Formulate research priorities to optimize neonatal red blood cell transfusion strategies.
All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
AM21-47: Red Blood Cell Transfusion of Preterm Infants in the 21st Century: High Level Evidence to Guide Practice Evaluation